Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Vera Therapeutics, Inc. Director's Dealing 2021

May 14, 2021

31944_dirs_2021-05-13_16feecf4-9c88-4a9d-950e-412ac553d254.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Vera Therapeutics, Inc. (VERA)
CIK: 0001831828
Period of Report: 2021-05-13

Reporting Person: SEIDENBERG BETH C (Director)

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Series A Preferred Stock $ Class A Common Stock (423642) Indirect
Series B Preferred Stock $ Class A Common Stock (100526) Indirect
Series C Preferred Stock $ Class A Common Stock (818984) Indirect
Stock Option (right to buy) $2.8968 2030-12-15 Class A Common Stock (69043) Direct

Footnotes

F1: The Series A Preferred Stock is convertible into Class A Common Stock on a 11.5869:1 basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on May 7, 2021) and has no expiration date. Upon filing of the Issuer's Restated Certificate of Incorporation in connection with the Issuer's initial public offering, all shares of Series A Preferred Stock will be converted into shares of Class A Common Stock of the Issuer.

F2: Consists of 409,620 shares of Class A Common Stock issuable upon the deemed conversion of the Issuer's Series A Preferred Stock held by Kleiner Perkins Caufield & Byers XVI, LLC ("KPCB XVI") and 14,022 shares of Class A Common Stock issuable upon the deemed conversion of the Issuer's Series A Preferred Stock held by KPCB XVI Founders Fund, LLC ("XVI Founders"). All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee". The managing member of KPCB XVI is KPCB XVI Associates, LLC ("XVI Associates"). L. John Doerr, Beth Seidenberg, Randy Komisar, Theodore E. Schlein and Wen Hsieh, the managing members of KPCB XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI. Such managing members disclaim beneficial ownership of all shares held by KPCB XVI except to the extent of their pecuniary interest therein.

F3: The Series B Preferred Stock is convertible into Class A Common Stock on a 11.5869:1 basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on May 7, 2021) and has no expiration date. Upon filing of the Issuer's Restated Certificate of Incorporation in connection with the Issuer's initial public offering, all shares of Series B Preferred Stock will be converted into shares of Class A Common Stock of the Issuer.

F4: Consists of 97,199 shares of Class A Common Stock issuable upon the deemed conversion of the Issuer's Series B Preferred Stock held by KPCB XVI and 3,327 shares of Class A Common Stock issuable upon the deemed conversion of the Issuer's Series B Preferred Stock held by XVI Founders. All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee". The managing member of KPCB XVI is XVI Associates. L. John Doerr, Beth Seidenberg, Randy Komisar, Theodore E. Schlein and Wen Hsieh, the managing members of KPCB XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI. Such managing members disclaim beneficial ownership of all shares held by KPCB XVI except to the extent of their pecuniary interest therein.

F5: The Series C Preferred Stock is convertible into Class A Common Stock on a 11.5869:1 basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on May 7, 2021) and has no expiration date. Upon filing of the Issuer's Restated Certificate of Incorporation in connection with the Issuer's initial public offering, all shares of Series C Preferred Stock will be converted into shares of Class A Common Stock of the Issuer.

F6: Consists of 791,876 shares of Class A Common Stock issuable upon the deemed conversion of the Issuer's Series C Preferred Stock held by KPCB XVI and 27,108 shares of Class A Common Stock issuable upon the deemed conversion of the Issuer's Series C Preferred Stock held by XVI Founders. All shares are held for convenience in the name of "KPCB Holdings, Inc., as nominee". The managing member of KPCB XVI is XVI Associates. L. John Doerr, Beth Seidenberg, Randy Komisar, Theodore E. Schlein and Wen Hsieh, the managing members of KPCB XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI. Such managing members disclaim beneficial ownership of all shares held by KPCB XVI except to the extent of their pecuniary interest therein.

F7: 1/36 of the shares subject to the option vested on January 16, 2021, and 1/36 of the shares vest monthly thereafter.